Ocugen found using ticker (OCGN) have now 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 0.7 with the average target price sitting at 3.55. Now with the previous closing price of 3.25 this would imply there is a potential upside of 9.2%. The 50 day moving average now sits at 2.31 while the 200 day moving average is 0.81. The market capitalisation for the company is $851m. Find out more information at: http://www.ocugen.com
Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.